TABLE 1.
Clinical characteristics of the human study cohort1
| Placebo (n = 15) | Nitrite (n = 20) | P | |
|---|---|---|---|
| Age, y | 67 ± 10 | 62 ± 9 | 0.199 |
| Sex, male | 11 (73.3) | 19 (95.0) | 0.070 |
| Height, cm | 167 ± 10 | 172 ± 10 | 0.130 |
| Weight, kg | 89 ± 15 | 88 ± 16 | 0.959 |
| Body surface area, m2 | 2.02 ± 0.22 | 2.04 ± 0.23 | 0.714 |
| SBP baseline, mm Hg | 131 ± 17 | 125 ± 19 | 0.356 |
| SBP postinfusion, mm Hg | 123 ± 22 | 117 ± 21 | 0.467 |
| DBP baseline, mm Hg | 76 ± 9 | 73 ± 10 | 0.383 |
| DBP postinfusion, mm Hg | 70 ± 9 | 68 ± 12 | 0.592 |
| HR baseline, bpm | 61 (56, 68) | 64 (57, 72) | 0.227 |
| HR postinfusion, bpm | 58 (55, 63) | 64 (55, 74) | 0.178 |
| Diabetes mellitus | 4 (26.7) | 7 (35.0) | 0.599 |
| Myocardial infarction | 7 (46.7) | 7 (35.0) | 0.486 |
| Hypertension | 11 (73.3) | 10 (50.0) | 0.163 |
| Smoking status | 0.325 | ||
| Never | 5 (33.3) | 10 (50.0) | |
| Ex-smoker | 9 (60.0) | 7 (35.0) | |
| Current | 1 (6.7) | 3 (15.0) | |
| Aspirin | 12 (80.0) | 13 (65.0) | 0.331 |
| β-blockers | 14 (93.3) | 16 (80.0) | 0.265 |
| Oral nitrates | 2 (13.3) | 4 (20.0) | 0.605 |
| Calcium channel blockers | 4 (26.7) | 4 (20.0) | 0.642 |
| ACEi/ARB | 8 (53.3) | 12 (60.0) | 0.693 |
| Statins | 15 (100.0) | 19 (95.0) | 0.380 |
1Values are n (%), mean ± SD, or median (IQR). ACEi, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor type 2 blockers; DBP, diastolic blood pressure; HR, heart rate; SBP, systolic blood pressure.